Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 703.31M |
| Revenue (ttm) | 49.80M |
| Net Income (ttm) | -50.34M |
| Shares Out | 423.68M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 989,026 |
| Open | 1.690 |
| Previous Close | 1.690 |
| Day's Range | 1.655 - 1.720 |
| 52-Week Range | 0.514 - 1.950 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 4.15 (+150.0%) |
| Earnings Date | May 1, 2026 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart fail... [Read more]
Financial Performance
In 2025, Lexicon Pharmaceuticals's revenue was $49.80 million, an increase of 60.24% compared to the previous year's $31.08 million. Losses were -$50.34 million, -74.88% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LXRX stock is "Strong Buy." The 12-month stock price target is $4.15, which is an increase of 150.00% from the latest price.
News
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analys...
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The company is advancing late-stage programs in HCM, type 1 diabetes, and neuropathic pain, with strong regulatory engagement and strategic partnerships. Key milestones include imminent Phase 3 data, NDA resubmission, and new obesity drug trials with Novo Nordisk.
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kid...
Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025
Advanced late-stage programs in cardiometabolic and chronic pain, reduced operating expenses by $129.5M year-over-year, and strengthened cash position by over $100M. Key milestones include over 50% enrollment in SONATA-HCM, NDA resubmission for Zynquista in 2026, and pilavapadin Phase III readiness.
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 read...
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 ...
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, Mar...
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the closing of its previously announced underwritten public offering ...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering ...
Lexicon Announces Proposed Public Offering of Common Stock
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and se...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food ...
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today anno...
Lexicon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a focused pipeline in cardiometabolic and pain therapies, with late-stage trials for HCM and DPNP, and a resubmission plan for Zynquista in type 1 diabetes. Strategic partnerships and a strong cash position support growth and global expansion.
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA ...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to s...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conf...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a t...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagl...
Lexicon Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key programs advanced include Zynquista for type 1 diabetes, with new FDA engagement and data from a large Danish study, and the SONATA HCM trial, targeting a pivotal KCCQ benefit. Pilavapadin shows strong phase II results in DPNP, and LX9851 was licensed to Novo Nordisk for obesity.
Lexicon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
FDA supports using Steno-1 data for Zynquista NDA, targeting 2026 approval if trends hold. Significant market opportunity exists in type 1 diabetes, and HCM programs are progressing with SONATA-HCM on track for 2026 enrollment completion. Cash runway extends into 2026.
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37...
Lexicon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Multiple late-stage programs are advancing, including pilavapadin for neuropathic pain and sotagliflozin for HCM and type 1 diabetes, with key regulatory milestones and data readouts expected between late 2025 and early 2027. FDA collaboration and favorable policy trends support progress.